Abbott raises annual earnings outlook as COVID-19 test sales rebound
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Abbott Labs (ABT) PT Raised to $145 at Jefferies
October 21, 2021 7:56 AM EDTJefferies analyst Raj Denhoy raised the price target on Abbott Labs (NYSE: ABT) to $145.00 (from $135.00) while maintaining a Buy rating following earnings.
The analyst commented, "Key post call datapoints: 1) COVID testing still elevated with $1-$1.4bn baked into 4Q guide, 2) screening versus symptomatic testing... More
